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Abstract Mast cells (MCs) are a part of the innate immune
system. The MC functions toward cancer are partially based on
the release of chymase and tryptase. However, the MC effect on
breast cancer is controversial. The aim of our study was to inves-
tigate the presence of MCs in breast cancer tumors of different
molecular subtypes and their relationships with other pathologi-
cal prognostic factors. Tryptase- and chymase-positive mast cell
densities were evaluated by immunohistochemistry in 108 pri-
mary invasive breast cancer tissue samples. Positive cells were
counted within the tumor bed and at the invasive margin. For all
analyzed MC subpopulations, we observed statistically signifi-
cant differences between individual molecular subtypes of breast
cancer. The significantly higher numbers of intratumoral
chymase- and tryptase-positive mast cells were observed in lu-
minal A and luminal B tumors compared to triple-negative and
HER2+ non-luminal lesions. A denser MC infiltration was asso-
ciated with lower tumor grade, higher ER and PR expression,
lower proliferation rate as well as the lack of HER2 overexpres-
sion. The results obtained in our study indicate a possible asso-
ciation of chymase- and tryptase-positive MCs with more favor-
able cancer immunophenotype and with beneficial prognostic
indicators in breast cancer.
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Introduction
Breast cancer is the most common cancer in females in the
developed world. It is heterogeneous in terms of prognosis,
morphology, and molecular biology; on the basis of its gene
expression pattern, four main molecular subtypes were distin-
guished: luminal A, luminal B, HER2 non-luminal, and basal-
like. This classification may be emulated by an immunohisto-
chemical panel, which became a standard in routine pathology
[1, 2].
Tumor microenvironment consists of fibroblast, endotheli-
al, and immune cells as well as extracellular matrix (ECM) in
the immediate surroundings of cancer. It influences anti-tumor
host defense, tumor development, neoangiogenesis, and met-
astatic propensity, and may affect patient’s outcome [1–3].
Mast cells (MCs) are bone marrow-derived cells common-
ly associated with allergic reactions and responses to parasitic
infestations. MC granules store numerous mediators, includ-
ing heparin, histamine, proteases, chemokines, and growth
factors, which are released uponMC activation and contribute
to tissue repair, wound healing, and angiogenesis. They mod-
ulate functions of other immune cells by either enhancing
immunologic response or inducing immune tolerance. MCs
are also one of the first cells to infiltrate cancer and can either
promote or suppress tumor growth [4–8].
Proteases constitute approximately one fourth of MCs
protein content. Based on the expression of chymase
and tryptase, the mast-cell-specific serine proteases, hu-
man MCs are divided into MCT, which expresses only
tryptase and MCTC, which expresses both tryptase and
chymase. These populations predominate in different
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anatomical locations and vary according to their func-
tions [4, 6, 9]. Tryptase participates in ECM remodeling
and is a potent proangiogenic factor, in part by
protease-activated-receptor 2 (PAR-2) activation [9–11].
MC tryptase was also reported to activate tumor-
associated fibroblasts [12]. Chymase is thought to be
important mainly for ECM remodeling; however, it
may also induce angiogenesis by activating metallopro-
teinases (MMPs), such as MMP-9, which releases
proangiogenic mediators from stroma [6, 12, 13].
Some MC proteases are stored in complexes with heparin
[14]. Heparin suppresses proliferation and reduces the number
of breast cancer cell colonies. It was hypothesized that heparin
might interrupt interactions between tumor-associated fibroblasts
and cancer cells, thus impairing tumor development [15].
The aim of the study was to investigate the density of MCs
expressing tryptase and chymase in breast cancers of different
molecular subtypes and to examine their relationships with
more standard prognostic factors.
Preliminary results from this study were presented at the
6th Jagiellonian University Medical College Doctoral
Students’ Conference.
Materials and methods
Materials
The material consisted of routinely processed, formalin-
fixed paraffin-embedded primary invasive breast carcino-
mas diagnosed between 2002 and 2014. The archival he-
matoxylin–eosin-stained slides were re-evaluated and rep-
resentative, well-preserved specimens were chosen for im-
munohistochemistry. For nuclear grading, Nottingham
Histologic Grade system was used, while staging was per-
formed according to 2010 AJCC system [16].
Immunohistochemistry
Immunohistochemistry for tryptase, chymase, estrogen receptor
(ER), progesterone receptor (PR), and Ki67 protein was per-
formed according to the protocol routinely used in our laboratory.
The selected blocks were cut into 4-μm-thick sections. Antigen
retrieval was performed by incubating the slides in citrate buffer
(pH 6.0; 0.01 M) or EDTA (pH 8.0; 0.01 M) at 97 °C in a water
bath for 40 and 30 min, respectively, or by enzymatic digestion
with proteinase (21 °C, 7 min). Primary antibodies used in the
study are listed in Table 1.
UltraVision Quanto detection system (LabVision;
ThermoScientific, USA) and 3,3′-diaminobenzidine as chro-
mogen were used, and the slides were counterstained with
Mayer hematoxylin (Thermo Fisher Scientific, Waltham,
USA) and coverslipped.
Immunohistochemistry for HER2 was performed on
BenchMark BMK Classic autostainer (Ventana, USA) using
UltraVIEW DAB Detection Kit (Ventana Medical Systems
Inc., USA).
For specimens with HER2 status 2+ by immunohisto-
chemistry, fluorescence in situ hybridization (FISH) was
conducted. FISH was performed using a PathVysion
HER-2 DNA Probe Kit II (Abbott Molecular, USA) ac-
cording to the manufacturer’s protocol. In short, paraffin
blocks were cut into 4-μm-thick sections. Hybridization
was performed at 37 °C for 14 to 18 h with a locus specific
identifier (LSI) DNA probe (~226 kb) SpectrumOrange
direct ly labeled (Abbott Molecular, USA) and a
Chromosome Enumeration Probe 17 (CEP17) satellite
DNA probe (~5.4 kb) SpectrumGreen directly labeled
(Abbott Molecular, USA). 4,6-Diamino-2-phenylidole
was used as nuclear counterstain. The LSI HER-2/neu
and CEP17 signals were counted on fluorescence micro-
scope equipped with specific filter sets and HER-2/neu to
CEP17 ratio >2.0 was considered as HER2/neu overex-
pression [17].
Table 1 Antibodies used in the
study Clone Dilution Antigen
retrieval
Incubation
time (min)
Manufacturer
Tryptase AA1 1:100 Proteinase 60 Novocastra (Leica
Biosystems, Germany)
Chymase CC1 1:100 Citrate 30 LabVision
(ThermoScientific, USA)
Estrogen
receptor
6F11 1:25 Citrate 60 Novocastra (Leica
Biosystems, Germany)
Progesterone
receptor
PgR636 1:50 Citrate 60 Dako, USA
Ki67 MIB-1 1:100 EDTA 60 Dako, USA
HER2/neu PATHWAY4B5 Ventana Medical System
Inc., USA
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Evaluation of immunostaining
The slides stained for tryptase and chymase were scanned on
Nikon Labophot-2 optical microscope (Tokyo, Japan) at low
magnification (×100), and the areas with the highest number
of positive cells were chosen. Then, positively stained cells
were counted in five high-power fields (HPF) (400 × 0.2 mm2
field area), which represented 1 mm2 of the examined tissue.
The positive cells located no further than 1 HPF from the
tumor edge were regarded as invasive margin, while positive
cells located within neoplastic tissue further than 1 HPF from
the tumor edge inwards were considered as intratumoral
population.
Positive ER and PR expression were set when ≥1% of
neoplastic cells showed positive immunostaining. The thresh-
old for discriminating between low and high Ki67 expression
was set at ≥14% of positive cells. Scoring of the HER2 stain
was performed by standard method [17].
Definition of breast cancer molecular subtypes
The cases were classified into molecular subtypes according
to St Gallen 2013 International Expert Consensus: luminal A
(ER+ and PR ≥20%, Ki67 < 14%, HER2−), luminal B/ HER2
− (ER+, HER2− with PR <20% and/or Ki67 ≥ 14%), luminal
B/HER2+ (ER+ or PR+, HER2+), HER2+ non-luminal (ER
−/PR−/HER2+), and triple-negative breast cancer (ER−/PR
−/HER2−) [18].
Statistical analysis
To assess the differences in positive cells’ infiltrate between
groups, ANOVA Kruskal–Wallis and Mann–Whitney U tests
were performed. The correlations between groups were eval-
uated by using Spearman rank test. All analyses were per-
formed using Statistica 10 (StatSoft Inc., USA). p values
<0.05 were considered statistically significant.
Results
Study group
The study group consisted of 108 cases. The mean age of
patients at the time of diagnosis was 55.3 years, ranging from
29 to 87 years. Sixty cases (55.5%) were stage pT1, 45 cases
(41.7%) pT2, and 3 cases (2.8%) pT3. Lymph node status was
pN0 in 54 cases (50.0%), pN1 in 31 cases (28.7%), pN2 in 9
cases (8.3%), and pN3 in 13 cases (12.0%).
Distribution of molecular subtypes was as follows: luminal
A in 30 cases (27.8%), luminal B/HER2− in 19 cases (17.6%),
luminal B/HER2+ in 10 cases (9.3%), HER2+ non-luminal
(HER2+) in 20 cases (18.5%), and triple-negative breast
cancer (TNBC) in 29 cases (26.8%). On the basis of the his-
tologic type, 91 cases (84.3%) were classified as Bnot other-
wise specified^ (NOS), 15 cases (13.9%) as lobular, and 2
cases (1.8%) as Bother.^ Nottingham Histologic Grade was
G1 in 17 cases (15.7%), G2 in 37 cases (34.3%), and G3 in
54 cases (50%). The patients and tumor characteristics are
shown in Table 2.
MC subpopulations in different breast cancer subtypes
First, we investigated whether the mast cell counts differed
between cancers of luminal (ER+ or PR+) and non-luminal
(ER− and PR−) immunophenotype. A statistically significant
difference was observed for both chymase- and tryptase-
positive MCs in either intratumoral location or at the invasive
margin (Fig. 1). In all cases, the luminal subtype of tumors
was associated with relatively higher MC count (Table 3).
Thorough analysis of each of the investigated MC popula-
tions showed significant differences in the density of infiltra-
tion between molecular subtypes of cancer; this was most
evident for intratumoral cells. The number of intratumoral
Table 2 Clinicopathologic features of the study group
Characteristic Number of cases Percent
Age
Range: 29–87
Mean: 55.3
Tumor size
pT1 60 55.5
pT2 45 41.7
pT3 3 2.8
Lymph node status
pN0 54 50.0
pN1 31 28.7
pN2 9 8.3
pN3 13 12.0
Nottingham Histologic Grade
G1 17 15.7
G2 37 34.3
G3 54 50.0
Histological type
Ductal 91 84.3
Lobular 15 13.9
Other 2 1.8
Molecular subtype
Luminal A 30 27.8
Luminal B 19 17.6
Luminal B/ HER2+ 10 9.3
HER2+ non-luminal 20 18.5
Triple negative 29 26.8
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chymase-positive MCs was the highest in luminal B cancers,
which differed significantly from TNBC (p < 0.002) and
HER2+ non-luminal (p < 0.025) tumors. Luminal A cancers
contained significantly more chymase-positive MCs than
TNBC cancers (p < 0.04). The intratumoral tryptase-positive
MC density was the highest in luminal A tumors and was
significantly higher than that in TNBC (p < 0.001) and
HER2+ non-luminal (p < 0.04) cases. The abundance of these
cells was also significantly higher in luminal B as compared to
TNBC tumors (p < 0.015). There was a significant difference
in MC density at the invasion front between all the molecular
breast cancer subtypes, but no significant difference in post
hoc analysis was observed (Fig. 2, Table 3).
The number of MCs at the invasive margin, either
chymase- or tryptase-positive, was significantly increased in
tumors without HER2 overexpression (p < 0.025 and
p < 0.015, respectively) compared to that in HER2
overexpressed tissues (Table 3).
We also observed also that intratumoral tryptase-positive
MCs were strongly associated with tumors of low Ki67 ex-
pression (p < 0.001) (Table 3).
The numbers of all investigated MC populations showed
significant positive correlations with ER and PR expression,
as well as a negative correlation with mitotic index. For inves-
tigated subpopulations, either in intratumoral area or at the
invasion edge, tryptase-positive MCs correlated negatively
with Ki67 expression. However, for chymase-positive MCs,
such correlation was observed only within the tumor bed.
MC subpopulations and other pathological prognostic
factors
Investigated tumors were stratified according to their size into
tumors of diameter ≤2 cm (pT1) and >2 cm (pT > 1). We
observed statistically significant differences in tryptase-
positive cell densities in both intratumoral compartment
Table 3 MC densities in breast
cancers of different molecular
subtype, immunophenotype,
Ki67, and HER2 expression
Chymase Tryptase
Intratumoral Invasive margin Intratumoral Invasive margin
Mean
(SD)
p Mean
(SD)
p Mean
(SD)
p Mean
(SD)
p
Molecular subtype
Luminal A 22.59
(10.38)
<0.001 23.21
(7.87)
<0.025 40.40
(16.97)
<0.001 36.27
(20.62)
<0.015
Luminal B 27.72
(12.76)
25.68
(11.95)
36.94
(17.56)
38.74
(19.97)
Luminal B/HER2+ 20.80
(12.45)
19.50
(7.55)
31.10
(20.89)
26.70
(11.49)
HER2+ non-luminal 15.30
(7.89)
18.70
(9.76)
25.90
(11.43)
24.65
(9.24)
Triple negative 14.56
(9.82)
19.03
(7.35)
22.50
(13.42)
27.17
(11.28)
Immunophenotype
Luminal 23.89
(11.64)
<0.001 23.38
(9.43)
<0.005 37.72
(17.86)
<0.001 35.44
(19.34)
<0.004
Non-luminal 14.87
(8.97)
18.90
(8.32)
23.92
(12.61)
26.14
(10.46)
HER2 overexpression
No 20.91
(11.88)
NS 22.25
(9.15)
<0.025 32.99
(17.69)
NS 33.49
(18.01)
<0.015
Yes 17.13
(9.79)
18.97
(8.96)
27.63
(15.08)
25.33
(9.89)
Ki67 expression
Low 22.41
(10.97)
NS 22.79
(8.27)
NS 39.17
(16.29)
<0.001 34.89
(19.61)
NS
High 18.56
(11.47)
20.43
(9.44)
27.68
(16.28)
29.22
(14.62)
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(p < 0.008) and at the invasion front (p < 0.02) between the
two groups. The intratumoral tryptase-positive MC density
was higher in pT1 tumors (mean 35.5, SD 18.2) as compared
to pT > 1 lesions (mean 26.6, SD 14.3). Similarly, for tryptase-
positive MCs at the tumor margin, higher density was ob-
served in smaller-sized cancers (pT1—mean 33.7, SD 17.2;
pT > 1—mean 28.1, SD 15.2). There were no statistically
significant differences in MC densities between cases with
and without nodal involvement.
There were significant differences in the densities of
tryptase-positive cells, both in intratumoral compartment and
at the invasive margin, as well as intratumoral chymase-
positive cell count between tumors of different Nottingham
Histologic Grades. The number of intratumoral chymase-
positive cells was significantly higher in G1 (p < 0.015) and
G2 (p < 0.008) tumors as compared to G3 lesions. Tryptase-
positive MC densities for both intratumoral compartment and
invasion front were significantly higher in G1 than in G3
cancers (p < 0.015 and p < 0.05, respectively) (Fig. 3, Table 4).
In respect of tumor histological type, intratumoral tryptase-
positive cells were significantly associated with lobular phe-
notype (Table 4).
Discussion
The studies concerning MC infiltration in various breast cancer
molecular subtypes were scarce and the results were encumbered
by varied subtype classifications. In our study, we noted that
chymase- and tryptase-positive MC infiltration differed between
breast cancers of respective molecular subtypes in both
intratumoral area as well as at the invasive margin, and that
higher MC numbers were associated with less aggressive cancer
types. Similar to our results, della Rovere et al. observed high
MC density in breast cancer expressing high levels of hormone
receptors. As a result, the authors considered MC infiltration in
this neoplasm as a protective factor against tumor progression,
potentially due to MC cytolytic activity against malignant cells
Fig. 1 Mast cells in invasive breast cancer. Low (a) and high (b) chymase-positivemast cells infiltration, low (c) and high (d) tryptase-positivemast cells
infiltration. Immunohistochemistry for tryptase and chymase, magnification ×100
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[19, 20]. Raica et al. noted that density of intratumoral, but not
peritumoral, tryptase-positive MCs was higher in luminal A, lu-
minal B, and HER2-positive breast cancers compared to basal-
like breast cancers [21]. This was partially analogous to our
results, which suggested that non-luminal HER2-positive sub-
type was associated with low tryptase-positive MC content. In
Fig. 2 Density of investigated
MC subpopulations in breast
cancer specimens representing
different molecular subtypes:
Lum A luminal A, Lum B luminal
B/HER2−, Lum B/HER2 luminal
B/HER2+, HER2 HER2+ non-
luminal, TNBC triple-negative
subtype. Central point is the ar-
ithmetic mean, box is the arith-
metic mean ± standard error, and
whisker is the arithmetic
mean ± standard deviation.
ANOVA Kruskal–Wallis test, p-
values are shown in Table 3
Table 4 MCdensity according to
tumor grade and breast cancer
histological type
Chymase Tryptase
Intratumoral Invasive margin Intratumoral Invasive margin
Mean
(SD)
p Mean
(SD)
p Mean
(SD)
p Mean
(SD)
p
Nottingham Histologic Grade
1 24.41
(10.24)
<0.002 23.06
(8.67)
NS 39.65
(17.93)
<0.007 34.53
(11.46)
<0.02
2 23.46
(11.81)
22.36
(9.68)
34.44
(17.59)
36.19
(22.92)
3 15.87
(10.22)
20.09
(8.98)
26.83
(15.26)
26.78
(10.72)
Histological type
NOS 19.07
(11.12)
NS 20.69
(8.57)
NS 30.56
(17.14)
<0.05 29.48
(11.97)
NS
Lobular 24.79
(11.65)
25.71
(12.28)
38.73
(15.93)
42.93
(31.32)
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the quoted study, significant correlations between peritumoral
tryptase-positive MCs and lymphatic microvessel densities were
found in luminal A and basal-like cancers. Such observation
might indicate MC involvement in lymphangiogenesis and
lymphovascular spreading of breast cancer, particularly of lumi-
nal A type [21]. Other studies also outlined the correlation be-
tween tryptase-positive MCs and microvessel density in breast
cancer [22, 23].
We observed that all analyzed populations of MCs corre-
lated positively with ER and PR expression and negatively
with mitotic index. Additionally, tryptase-positive MCs both
of the intratumoral area and at the invasion front were nega-
tively associated with tumor size, while tryptase-positive as
well as intratumoral chymase-positive MCs showed an in-
verse correlation with Ki67 expression. These findings sup-
ported the aforementioned hypothesis of the protective role
assumed by MCs against cancer progression. Similarly, other
studies also suggested a negative correlation of tryptase-
positive MCs with tumor size [24], along with a positive cor-
relation with PR [25] and ER expression [24]. Although sev-
eral studies failed to show independent prognostic signifi-
cance of MCs in breast cancer [24–26], and few works have
even shown that peritumoral MC infiltration was associated
with poor short-term survival [27], MCs were still proposed
by some authors as an additive favorable prognostic factor
[19, 25]. It was further postulated that even a single MC in
tumor surrounding might have a beneficial impact on the
prognosis [28]. Rajput et al. observed a positive but not sig-
nificant correlation between MCs and HER2 expression [28].
However, our study suggested that chymase- and tryptase-
positive MC densities at the tumor front were associated with
tumors that did not indicate HER2 overexpression. Some oth-
er studies observed an inverse correlation between tryptase-
positive MCs and Ki67 expression [24], while others did not
[19]. Contrary to our results and the aforementioned literature,
Ranieri et al. did not find any associations between MC num-
ber and tumor size, histological grade, ER/PR status, or HER2
overexpression in early breast cancer [23].
Our study indicated that low- and intermediate-grade breast
cancers contained high numbers of MCs in both intratumoral
location and at the invasive margin. In consistence with our
results, some authors reported that tryptase-positive MCs cor-
related negatively with tumor histological Elston grade [24,
25]. A plausible explanation could be that low-grade breast
cancer elicited more effective innate immune response, or that
high-grade cancer suppressed such response. Strikingly,
Xiang et al. observed more numerous peritumoral MCs in
G3 breast cancers than lower grades, and reported more inten-
sive tryptase immunostaining in the surrounding of node-
positive tumors as compared to node-negative ones. In this
experimental study, tryptase itself did not increase prolifera-
tive activity of breast cancer cell lines. However, in the pres-
ence of heparin, tryptase increased cancer cell migration and
expression of activated MMP-1. As tryptase was activated by
Table 5 Immunohistochemical studies, which evaluated mast cells in breast cancer
Authors Material Mast cells’
marker
Conclusions Reference
Bowers H. et al.,
1979
Axillary lymph nodes of 43
breast cancer patients
Toluidine
blue
Higher MC number is associated with better patients’ survival [30]
Samoszuk M.,
Corwin M.,
2003
35 breast cancer tissue sections
of varying stages
Tryptase A tendency toward peritumoral accumulation of MCs in preinvasive
and intratumoral accumulation in invasive tumors
[31]
Amini RM. et al.,
2007
234 invasive breast cancer
tissues
Tryptase MCs are associated with estrogen receptor positivity and low tumor
grade
[25]
della Rovere F.
et al., 2007
50 cases of invasive ductal breast
cancer
Alcian
blue
Higher MC content is associated with high hormone-receptive cancers [19]
Ribatti D. et al.,
2007
80 sentinel lymph nodes of
breast cancer patients
Tryptase Higher MC number in micrometastatic lymph nodes; MC quantity
increases with angiogenesis
[32]
Rajput A. et al.,
2008
4444 invasive breast cancer
tissues
CD117 Presence of MCs in tumor stroma associated with better patients’
survival
[28]
Ranieri G. et al.,
2009
88 breast cancer patients’ biopsy
specimens
Tryptase MCs are associated with angiogenesis [23]
Xiang M. et al.,
2010
80 breast cancer tissues Tryptase MC number positively correlated with tumor grade and was associated
with nodal involvement
[29]
Löfdahl B. et al.,
2012
190 lymph-node-negative breast
cancer tissue samples
Tryptase Negative associations between MC number and adverse prognostic
factors
[24]
Raica M. et al.,
2013
55 ductal invasive breast cancer
tissues
Tryptase Interplay between MCs and lymph vessels is specific for each
molecular subtype of breast cancer
[21]
Marech I. et al.,
2014
105 cases of breast cancer Tryptase Mast cell tryptase is involved in angiogenesis [22]
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low pH and heparin, the authors concluded that tryptase pro-
moted metastatic spread after microcirculation failed to re-
move acidic substances. This could potentially explain the
higher MC count in more aggressive, more rapidly growing,
grade 3 carcinomas observed in the study [29]. The findings
from other immunohistochemical studies in breast cancer are
summarized in Table 5.
Although the role of MCs in breast cancers has been inves-
tigated by several authors, the obtained results appeared to be
ambiguous. Roy et al. [33] used an experimental model of
arthritic mice for their study, which showed an elevated num-
ber of MCs within primary mammary tumors and at the sites
of metastasis in comparison with the control group. This may
be explained by the increased MC migration toward tumor
and their activation within malignant lesion. MCs were sug-
gested to attract stem cell factor (SCF) expressing breast can-
cer cells, thus facilitating the spread of the tumor. As SCF/c-kit
signaling is considered to be one of the most potent
chemoattractants and activators of MCs, SCF-positive neo-
plastic cells contributed, in turn, to subsequent infiltration,
differentiation, and survival of MCs, which would eventually
enhance metastatic potential of breast cancer [33]. Samoszuk
et al. reported that MCs could counteract tumor hypoxia by
releasing anticoagulants, which improved the blood flow. The
authors also noted that tryptase-positive MCs in early breast
cancer were more abundant in peritumoral stroma, while in
invasive tumors, MCs were more extensively located within
tumor tissue [31]. In the skin of breast cancer patients,
chymase- and tryptase-positive MCs increased collagen pro-
duction by interacting with dermal fibroblasts [34, 35]. It was
also shown that MC tryptase has the capability to modify
breast cancer microenvironment by converting fibroblasts into
activated myofibroblasts, which, in turn, may promote tumor
development. However, the accumulation of degranulated
MCT at the invasion margin was interpreted as an evidence
for protective role against cancer growth [36]. Bowers et al.
observed significantly higher MC number in axillary lymph
nodes of breast cancer patients who survived for longer than
60 months post-mastectomy, in comparison with patients with
a shorter survival time span. As a result, the authors postulated
that MCs might be involved in host tumor resistance [30]. In
contrast, higher MC and microvessel counts in sentinel lymph
nodes with micrometastases as compared to non-metastatic
sentinel lymph nodes could suggest the participation of MCs
in metastasis formation [32].
Mast cells were also investigated in other types of cancer.
The MC count in squamous cell carcinoma of the lip was
found to be higher compared to that in normal tissue. The
distribution of MCs in this neoplasm differed with reference
to location: within the tumor nest, MCT prevailed over MCTC
cells, while MCTC predominated at the tumor front. It was
postulated that the latter might influence cancer invasion
Fig. 3 Density of investigated MC subpopulations in breast cancer
specimens representing different Nottingham Histologic Grade. Central
point is the arithmetic mean, box is the arithmetic mean ± standard error,
and whisker is the arithmetic mean ± standard deviation. ANOVA
Kruskal–Wallis test, p values are shown in Table 4
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[37]. Mast cells displayed different phenotypes in normal,
hyperplastic, and malignant prostate tissues, thus suggesting
alteration in MC phenotypes and their involvement in patho-
genesis of prostate cancer. Moreover, peritumoral tryptase-
and chymase-positive MCs correlated with increasing
Gleason score [38]. In the cervix, the overall MC level was
stable in pre-cancer, but increased significantly in invasive
cancer. The prevailing phenotype of mast cells was MCT,
and the authors hypothesized that this population may stimu-
late neovascularization and promote tumor progression and
metastasis [39]. In addition, in patients on hemodialysis with
renal cell carcinoma, MCTwere also reported to predominate;
an elevated SCF expression in specimens from hemodialyzed
patients could potentially account for this MCT increase. MCT
density correlated positively with proliferative index and
PAR-2 expression in tumor cells [40]. Melanomas were noted
to display lower numbers of both chymase- and tryptase-
positive intratumoral MCs as compared to common and dys-
plastic nevi. Interestingly, the number of these cells increased
from common to dysplastic nevi. The authors suggested that
the observed decrease of MCs in malignant melanoma might
be due to the self-sufficiency of this neoplasm to induce
neoangiogenesis or to break the host defense barrier [41].
Several authors focused on the associations between
MCs and angiogenesis, a phenomenon linked to pro-
gression in various neoplasms. In non-small cell lung
carcinoma, MCTC correlated with blood vessel count
both inside the tumor and at the invasive margin. In
contrast, MCT number correlated with blood vessel
count only at the invasive margin, potentially due to
angiogenesis being associated mainly with MCTC densi-
ty [42]. In an experimental mice skin cancer model, de
Souza et al. observed that tumor MCs were recruited to
the tumor microenvironment at their immature state, and
that the number of both immature and mature MCs in-
creased parallel to cancer progression. At early phases
o f t um o r d e v e l o pm e n t , t r y p t a s e p r om o t e d
neoangiogenesis, while in later stages it modulated ves-
sel growth. Both chymase and tryptase expressions in-
creased during tumor progression, and correlated with
either MC maturation or new vessel formation, indicat-
ing the involvement of these two proteases in cancer
progression [43]. Similarly in gastric carcinoma,
tryptase- and chymase-positive MCs increased with
s t a g e a nd g r a d e , a n d we r e a s s o c i a t e d w i t h
neoangiogenesis [44]. In colorectal adenocarcinoma,
tryptase-positive MCs were found mainly in the imme-
diate vicinity of blood vessels. However, as some of the
tumor vessels lacked associated inflammatory cells, it
was probable that inflammatory infiltration was not re-
quired for the induction of angiogenesis [45]. In con-
trast, neither tryptase- nor chymase-positive MC densi-
ties were related to microvessel counts in mesothelioma,
though tryptase-positive MCs were associated with a
better overall survival rate and a longer time till pro-
gression [46].
As it might be inferred from the aforementioned studies,
MC contribution to tumor progression was observed in many
neoplasms [12, 37, 38, 41, 43, 44]. However, in some tumors,
MCs were regarded as protective factor [46], with their unde-
fined role in breast cancer [24, 25, 29]. In various cancers MC
distribution [37], as well as their prognostic significance, may
vary depending on MC intratumoral [40, 41] or peritumoral
[38] location, and in some cancers their increasingmalignancy
was reported to be associated with MC phenotype alteration
[37, 38]. In breast cancer, an increase in the number of non-
degranulated MCs from normal to malignant tissue was ob-
served [36]. MC functions are strongly dependent on micro-
environmental factors, and both cytokines as well as hor-
mones may affect even mature MCs and influence their num-
ber, activation, suppression, mediators’ content, and pheno-
type [4, 47, 48]. Thus, it is not unlikely that on the basis on
their functions and phenotype, in various cancers, the exis-
tence of several subpopulations of MCs could be considered,
which might be partially analogous to distinction between M1
and M2 macrophages [47, 49].
In conclusion, our study outlined the associations of MCs
with positive prognostic factors in breast cancer. We also ob-
served that the breast cancer molecular subtypes differed in
their chymase- and tryptase-positive MC content. However,
further investigation is required to elucidate their impact on
the breast cancer prognosis.
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